VAXART INC (VXRT) Stock Price, Forecast & Analysis
USA - NASDAQ:VXRT - US92243A2006 - Common Stock
VXRT Key Statistics, Chart & Performance
The current stock price of VXRT is 0.32 USD. In the past month the price decreased by -19.09%. In the past year, price decreased by -52.26%.
VXRT Latest News, Press Relases and Analysis
VXRT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.92 | 415.95B | ||
| AMGN | AMGEN INC | 15.54 | 182.98B | ||
| GILD | GILEAD SCIENCES INC | 15.19 | 154.39B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 110.73B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.2 | 72.53B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.2 | 59.11B | ||
| INSM | INSMED INC | N/A | 40.92B | ||
| NTRA | NATERA INC | N/A | 28.48B | ||
| BIIB | BIOGEN INC | 9.7 | 23.80B | ||
| INCY | INCYTE CORP | 16.78 | 21.03B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.45 | 20.83B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.15 | 14.57B |
Related stock screener links
About VXRT
Company Profile
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 105 full-time employees. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The firm's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
Company Info
VAXART INC
170 Harbor Way, Suite 300
South San Francisco CALIFORNIA 94080 US
CEO: Andrei Floroiu
Employees: 105
Phone: 16505503500
VAXART INC / VXRT FAQ
Can you describe the business of VAXART INC?
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 105 full-time employees. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The firm's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
What is the stock price of VAXART INC today?
The current stock price of VXRT is 0.32 USD. The price decreased by -25.06% in the last trading session.
Does VXRT stock pay dividends?
VXRT does not pay a dividend.
What is the ChartMill technical and fundamental rating of VXRT stock?
VXRT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of VAXART INC (VXRT) based on its PE ratio?
VAXART INC (VXRT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.27).
Can you provide the growth outlook for VAXART INC?
The Revenue of VAXART INC (VXRT) is expected to decline by -37.03% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the Short Interest ratio of VAXART INC (VXRT) stock?
The outstanding short interest for VAXART INC (VXRT) is 2.83% of its float.
VXRT Technical Analysis
VXRT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VXRT. VXRT has a bad profitability rating. Also its financial health evaluation is rather negative.
VXRT Financial Highlights
Over the last trailing twelve months VXRT reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS increased by 49.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.66% | ||
| ROE | -127.41% | ||
| Debt/Equity | 0.01 |
VXRT Forecast & Estimates
9 analysts have analysed VXRT and the average price target is 3.06 USD. This implies a price increase of 856.25% is expected in the next year compared to the current price of 0.32.
For the next year, analysts expect an EPS growth of 15.8% and a revenue growth -37.03% for VXRT